[1]夏晓亮,夏云宝,陈利华,等.基于MRI特征的脑胶质瘤异柠檬酸脱氢酶1表达预测研究[J].医学研究与战创伤救治(原医学研究生学报),2020,22(3):262-267.[doi:10.3969/j.issn.1672-271X.2020.03.009]
　XIA Xiao-liang,XIA Yun-bao,CHEN Li-hua,et al.The study of correlation between magnetic resonance characteristics and expression of glioma IDH1[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(3):262-267.[doi:10.3969/j.issn.1672-271X.2020.03.009]

点击复制

基于MRI特征的脑胶质瘤异柠檬酸脱氢酶1表达预测研究()

分享到62.8K

参考文献/References:

[1]吴志军,张志强,李建瑞,等. 脑多发胶质瘤的磁共振影像特征及鉴别诊断[J]. 医学研究生学报,2019,32(8)：828-832.
[2]Weller M,Wick W,Aldape K,et al. Glioma[J]. Nat Rev Dis Primers,2015,1：15017. doi:10.1038/nrdp.2015.17.
[3]吴章泽,王一芳,王正伟,等. 人参皂甙Rh2对人胶质瘤细胞内钙离子浓度的影响[J]. 东南国防医药,2019,21(1)：12-16.
[4]Wen PY,Huse JT. 2016 World Health Organization Classification of Central Nervous System Tumors[J]. Continuum (Minneap Minn),2017,23(6,Neuro-oncology)：1531-1547.
[5]Hartmann C,Meyer J,Balss J,et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age：a study of 1,010 diffuse gliomas[J]. Acta Neuropathol,2009,118(4)：469-474.
[6]Kickingereder P,Sahm F,Radbruch A,et al. IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma[J]. Sci Rep,2015,5:16238. doi：10.1038/srep16238.
[7]Villa C， Miquel C，Mosses D，et al. The 2016 World Health Organization classification of tumours of the central nervous system[J]. Presse Med,2018,47(11-12 Pt 2)：e187-e200.
[8]Leonardi R, Subramanian C, Jackowski S,et al. Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylation[J]. J Biol Chem,2012,287(18)：14615-14620.
[9]Zhang C，Moore LM，Li X，et al. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma[J]. Neuro Oncol,2013,15(9)：1114-1126.
[10]Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme[J]. Science,2008,321(5897)：1807-1812.
[11]Kloosterhof NK, Bralten LB, Dubbink HJ,et al. Isocitrate dehydrogenase-1 mutations：a fundamentally new understanding of diffuse glioma?[J] Lancet Oncol,2011,12(1)：83-91.
[12]Koivunen P,Lee S, Duncan CG,et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation[J]. Nature,2012,483(7390)：484-488.
[13]Xu W,Yang H,Liu Y,et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases[J]. Cancer Cell,2011,19(1)：17-30.
[14]梅东东，龚静山，刘永光，等. 脑胶质瘤IDH基因突变与定量多模态MRI研究进展[J]. 中国医学影像技术,2017,33(10)：1550-1553.
[15]Sabha N, Knobbe CB, Maganti M, et al. Analysis of IDH mutation,1p/19q deletion,and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas[J]. Neuro Oncol,2014,16(7)：914-923.
[16]杨燕武，谢飞，汤俊佳，等. IDH1基因突变对胶质瘤诊断及预后意义[J]. 中国现代神经疾病杂志,2012,12(6)：712-718.
[17]Song TQ， Lei Y，Si G，et al. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma[J]. Cancer Sci,2012,103(2)：269-273.
[18]Nakae S， Murayama K， Sasaki H，et al. Prediction of genetic subgroups in adult supra tentorial gliomas by pre- and intraoperative parameters[J]. J Neurooncol,2017,131(2)：403-412.
[19]Lasocki A， Tsui A，Gaillard F，et al. Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma[J]. J Clin Neurosci,2017,39：170-175.
[20]Leu K，Ott GA，Lai A，et al. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas[J]. 2017,134(1)：177-188.
[21]Qi S，Yu L，Li H，et al. Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms[J]. Oncol Lett,2014,7(6)：1895-1902.
[22]Chen C，Shi Y，Li Y，et al. A glycolysis-based ten-gene signature correlates with the clinical outcome,molecular subtype and IDH1 mutation in glioblastoma[J]. J Genet Genomics,2017,44(11)：519-530.
[23]Lee S，Choi SH，Ryoo I，et al. Evaluation of the microenvironmental heterogeneity in high-grade gliomas with IDH1/2 gene mutation using histogram analysis of diffusion-weighted imaging and dynamic-susceptibility contrast perfusion imaging[J]. J Neurooncol,2015,121(1)：141-150.

相似文献/References: